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Calcium channel blockers versus other antihypertensive therapies on
progression of NLDDM associated nephropathy. Treatment of hyperten-
sion with ACE inhibitors in diabetic patients reduces proteinuria and
slows progression of nephropathy compared with agents that do not
maintain declines in proteinuria. Calcium channel blockers (CCB5) have
variable effects on protcinuria; their long-term effects on progression of
diabetic nephropathy are not known. The current study examines the
hypothesis that CCBs that maintain reductions in proteinuria slow pro-
gression of nephropathy associated with non-insulin dependent diabetes
mellitus (NIDDM) by a degree comparable to ACE inhibitors, given
similar levels of blood pressure control. To test this hypothesis we
randomized 52 patients with NIDDM associated nephropathy and hyper-
tension, mean age of 63 8 years, to either the ACE inhibitor, lisinopril
(N = 18), nondihydropyridine CCBs (NDCCBs), verapamil SR (N 8) or
diltiazem SR (N = 10), or the /3 blocker, atenolol (N = 16). Goal blood
pressure was  140/90 mm Hg. Patients were followed for a mean period
of 63 7 months. The primary end point was change in creatinine
clearance (Cr) slope in each group. There was no significant difference in
mean arterial pressure reduction among the groups over the study period
(P = 0.14). The mean rate of decline in C, was greatest in the atenolol
group (—3.48 ml/min/year/1.73 m2; P < 0.0001). There was no difference
in the C1., slopes between lisinopril and NDCCBs groups (P = 0.36).
Proteinuria was reduced to a similar extent in the lisinopril and NDCCBs
groups (P> 0.99). Therefore, in persons with renal insufficiency secondary
to NIDDM, similar levels of blood pressure control with either lisinopril
or NDCCBs slowed progression of renal disease to a greater extent than
atenolol. Moreover, this enhanced slowing of renal disease progression
correlated with sustained and significant reductions in proteinuria, find-
ings not observed in the atenolol group.
Diabetic renal disease is the leading cause of end-stage renal
disease in the western world [1]. Early studies using 13 blockers
and diuretics demonstrated that reduction of arterial pressure to
levels of less than 140/90 mm Hg was one of the most effective
ways to slow progression of diabetic renal disease [2]. Recently,
however, several long-term clinical studies in patients with either
insulin dependent diabetes mellitus (IDDM) or noninsulin depen-
dent diabetes mellitus (NIDDM) demonstrate that angiotensin
converting enzyme (ACE) inhibitors also slow progression of
diabetic renal disease [3—10]. Moreover, reduction in disease
progression by ACE inhibitors may be greater than that seen with
13 blockers and diuretics [5, 9, 10]. This may relate, in part, to the
relatively greater reductions in proteinuria seen with ACE inhib-
itors, which have been shown to correlate with a slowed decline in
renal function [6, 8—11].
Calcium channel blockers (CCBs) inhibit the vasoconstrictor as
well as both the hypertrophic and hyperplastic effects of angio-
tensin II and other mitogens on mesangial and vascular smooth
muscle cells through blockade of calcium dependent mechanisms
[12—141. Early studies, however, demonstrate marked differences
between the antiproteinuric effects of dihydropyridine CCBs
(nifedipine-like) and nondihydro-pyridine CCBs (NDCCBs) such
as verapamil and diltiazem [15, 16]. Recent data support the
concept that differences in antiproteinuric response between CCB
subclasses relate to their differential effects on glomerular perme-
ability, that is, dihydropyridine CCBs do not reduce permeability
whereas nondihydropyridine CCBs attenuate permeability [17,
18]. In NIDDM patients this failure to reduce permeability
increases exposure of glomerular cells to albumin which is gly-
cated. Glycated albumin has been shown to have direct toxic
effects on these cells as well as increase mesangial matrix produc-
tion [11, 19—21]. No long term studies have examined the effects
of CCBs on progression of NIDDM associated nephropathy in the
context of proteinuria reduction.
The present six-year study evaluates the impact of three differ-
ent classes of antihypertensive agents on progression of NIDDM
associated nephropathy and changes in proteinuria in the context
of similar levels of blood pressure control. CCBs that mimic the
aritiproteinuric effects of ACE inhibitors were selected for com-
parison, since, theoretically, they should provide similar benefit to
the kidney.
Methods
This report represents a six-year follow-up of patients with
NIDDM associated nephropathy who were prospectively random-
ized to one of three groups of antihypertensive treatments. The
study protocol and consent forms were reviewed and approved by
the Institutional Review Board of the Ochsner Clinic.
Study population
Both inclusion and exclusion criteria are listed in Table 1. The
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baseline demographic characteristics of the patients who com-
pleted the study arc summarized in Table 2. Seventy-six patients
were screened from both the nephrology and cardiology clinics of
the Alton Ochsner Medical Institutions, New Orleans, Louisiana,
52 of whom met the criteria and were randomized to one of the
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Table 1. Inclusion and exclusion criteria for patient population studied
Inclusion criteria
• Non-insulin dependent diabetes for  8 years
• Diabetic retinopathy (by ophthalmologic examination)
• Proteinuria  2.0 glday
• Renal insufficiency (creatinine clearance, < 1.16 mI/second [< 70 ml!
mini)
• Hypertension for  8 years
• Age  45 years
Exclusion criteria
• Heart failure (ejection fraction,  40%)
• History of poor diabetes control (blood glucose, 11 mmol/liter [198
mmol/literj or glycosylated hemoglobin, > 13%)
• History of difficult blood pressure control (maximum dose of 3
medications or blood pressure > 105 mm Hg with medication)
• Blindness
• Documented coronary artery disease
• Severe claudication (peripheral arterial disease)
• Orthostatic hypotension (diabetic neuropathy)
• Required intake of antiarrhythmic medications, calcium channel
blockers, or converting enzyme inhibitor
• Documented psychiatric disease
• Active urine sediment (casts, gross hematuria, eosinophils)
• Diastolic pressure > 125 mm Hg on three consecutive readings with
no antihypertensive medications
• Blood glucose control by insulin therapy alone
three groups. Each subject gave informed consent to participate in
the study after a thorough explanation of the protocol.
Study design and treatment plan
All antihypertensive medications were discontinued in each
patient two weeks prior to any baseline measurements. Patients
were monitored during this period with daily blood pressure
checks in both the supine and standing positions by means of a
blood pressure monitoring device (Dinemapp, Critikon, Inc.,
Tampa, FL, USA). If any individual had an average of three
sitting diastolic pressures of greater than or equal to 125 mm Hg,
they were excluded from the study.
After this two-week period, a complete physical examination
and laboratory screening tests, including a complete ophthalmo-
logic examination using fluoresccine angiography, were per-
formed in each subject. Laboratory evaluation included: a 24-hour
urine collection for protein, albumin, creatinine clearance, and
sodium; urinalysis; complete blood cell count; renal electrolyte
profile, which consisted of serum urea nitrogen, creatinine, so-
dium, potassium, chloride, and bicarbonate; fasting blood glucose
and hemoglobin A1. An electrocardiogram was performed annu-
ally unless otherwise indicated. A renal dietitian also instructed
patients to ingest a 90 mEq!day sodium, 0.8 g/kg/day protein, and
6300-kJ American Diabetes Association diet.
After baseline laboratory measurements were obtained and
instructions given, patients were randomized to receive one of
three antihypertensive treatments: lisinopril, atenolol or one of
two NDCCBs, verapamil SR or diltiazem SR. The dosage of each
drug was initially titrated over a two-week period and then
periodically throughout the study to ensure similar arterial pres-
sure control among groups.
After the drug titration phase, blood pressure and pulse rates
were monitored weekly for the first month and quarterly, there-
after. All patients had blood pressure measured by the same
person, using an appropriate sized blood pressure cuff. All
Table 2. Baseline Characteristics of Study Groups
L
(N = 18)
NDCCB
(N = 18)
Atenolol
(N = 16) p value
Demographic
Height cm 175 15 178 18 180 16 0.42
Weight kg 101 7 107 6 104 6 0.33
Age years 62 7 64 7 60 8 0.27
Male sex % 61 50 38 0.51
Race N
Black 50 50 63 0.69
White 50 50 37
Duration of NIDDM 14 3 14 5 13 4 0.59
years
Duration of HTN years 16 5 13 4 16 4 0.73
Metabolic
FBG mmol/liter 10.5 1.3 9.7 1.0 9.9 1.0 0.26
HbAIC % 11.1 1.1 10.7 1.1 10.3 1.3 0.03
Hemodynamics
Systemic
SBP mm Hg 155 11 156 11 161 13 0.26
DBP mm Hg 97 6 97 6 99 7 0.62
Renal
Serum creatinine 141 44 168 62 159 71 0.16
mmol/liter
C mI/s/1.73 m2 1.11 0.3 1.01 0.38 1.02 0.38 0.53
Upr,tcj,, V glday
V mmol/day
2.7 2.2
123 28
4.5 3.4
113 31
4.2 3.7
127 27
0.22
0.39
Data represent mean standard deviation.
ANOVA performed for within and between group differences
Abbreviation is FBG, fasting blood glucose.
readings were obtained in the morning between 9 am. and noon
and at least one hour after eating and two hours after medication
ingestion. All readings were performed in triplicate in both sitting
and standing positions after a 10-minute rest period. Values were
then averaged. The data presented in the Results section repre-
sent sitting blood pressure values, since there was no clinically
significant difference between sitting and standing values.
Renal function studies including proteinuria measurements
were performed every three months during the first year of the
study and every six months thereafter. All urinary determinations
of albumin were corrected for daily creatinine production. Uri-
nary protein was measured by means of a dye-binding colorimetric
method (Biotrol USA, West Chester, PA, USA), which required
a pyrogallol red-molybdate complex formation. The interassay
variability was 2.4%. The intra-assay variability was 3.7%. Urinary
albumin excretion was measured by means of a double-antibody
radioimmune assay (Diagnostic Products Corp., Los Angeles, CA,
USA). The intra-assay variability was 3.5%. The interassay vari-
ability was 4.8%.
Fasting blood glucose levels were monitored daily by the
patients throughout the study by placing a drop of blood onto a
plastic strip and inserting it into a blood glucose measuring device
(AccuCheck II; Boehringer Mannheim, Indianapolis, IN, USA)
device. At the initiation of the study, all patients were instructed
on the proper use of the AccuCheck II device. Furthermore, all
AccuCheck 11 blood glucose measurements were compared ini-
tially and every month thereafter with standard laboratory glucose
measurements.
Side effects due to drugs were monitored at each visit for blood
pressure determination. Patients were asked what new complaints
or problems had arisen since their last clinic visit.
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A Statistical analysis
The data were analyzed with SAS version 6.07 [21] and Splus
version 3.2 [221. Nominal characteristics are summarized by
12 percentages; continuous variables are summarized by means and
SD5 or by medians when the distributions are skewed. Dichoto-
mous baseline characteristics were compared with Fisher's exact
test, and continuous baseline characteristics were compared pri-
manly with Kruskal-Wallis nonparametric tests and secondarily
10 with ANOVA. When all the groups differed significantly, Wil-
coxon rank-sum tests were used for pairwise comparisons. A
Wilcoxon matched-pair signed rank test was used to assess
9 differences in side effect profiles among the groups. The time
courses of blood-pressure and renal function were compared by
reducing the data to slopes and intercepts of least-squares lines,
1989 and then using Kruskal-Wallis and ANOVA as described above.
B Lastly, a subgroup analysis was planned, prior to statistical
13 evaluation, and performed to assess whether patients with serum
creatinine values of> 133 mmol/liter had differences in their rate
of progression. A P value of less than 0.05 was considered to
12 indicate statistical significance for comparisons among the three
groups. Bonferroni corrections were used for pairwise compari-
ii sons, so a nominal significance level of 0.05/6 = 0.00833 was usedfor the pairwise comparisons. Such analyses were performed to
assess changes in the slope of creatinine clearance among theI 10 groups.
Results
Patients were randomized to one of three treatment groups
between September 1988 and October 1989. Eighteen patients
1989 1990 1991 1992 1993 1994 received lisinopnil, eighteen received NDCCBs (8 to verapamil
SR, 10 to diltiazem SR) and sixteen patients received atenolol.
C The baseline clinical and laboratory characteristics of these three
groups were similar (Table 2). One difference, however, was that
the atenolol group had a significantly lower baseline HbA1C value
12 (P = 0.03) compared to the other groups. No significant differ-
ences in HbA1C, however, were noted among the three groups at
ii any other time point throughout the study (Fig. 1). Moreover,
there were no significant differences in baseline fasting blood
glucose values among the groups (Table 2). This lack of difference
10 in fasting blood glucose values among the three groups persisted
throughout the study (P = 0.16). Lastly, there was no formal
9 monitoring of urine urea nitrogen content throughout the study.Twenty-four hour urine values of sodium and creatinine were
assessed. The distribution of urinary sodium excretion for each
group over the entire study is shown in Figure 2.
1989 1990 1991 1992 1993 1994 A total of 43 patients completed the study (median follow-up,
Year 64 months, range 36 to 73). Six patients did not complete the study
Fig. 1. The annual values of !IhA1C for each patient in the ACE inhibitor either because they failed to return for follow-up visits or other
group (A), 13 blocker group (B) and NDCCB groups (C). non-medical problems unrelated to drug side effects. Three of
these six, died after being terminated from the study for missing
more than three follow-up visits. Additionally, three of the 52
patients died by the end of the study. Thus, six of 52 patients
(11.6%) died by study end. Five of the six died within the last two
End points years of the study. Five other patients (9.6%) started dialysis by
The primary end-point of the study was defined as the rate of study end. Two patients, included in the six deaths, died shortly
decline in renal function as assessed by the slope of creatinine after dialysis was initiated.
clearance, corrected for body surface area. Secondary end-points
included doubling of serum creatinine from baseline, reductions Clinical management
in urinary protein excretion rate from baseline as well as progres- Blood pressures were under 140/90 mm Hg in all patients by
sion to death, dialysis, or transplantation, eight weeks into the study. The mean systolic and diastolic blood
1990 1991 1992 1993 1994
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Year
Fig. 2. The annual values of urinary sodium excretion for each patient in the
ACE inhibitor (A) group, blocker group (B) and IVDCCI? groups (C).
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Fig. 3. The annual values of systolic blood pressure for each patient in the
ACE inhibitor group (A), p blocker group (B) and NDCCB groups (C).
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pressure distributions in all patients throughout the study are
shown in Figures 3 and 4. The median systolic pressure at baseline
was 154 mm Hg in the lisinopril group, 159 mm Hg in the NDCCB
group and 155 mm Fig in the atenolol group. The median diastolic
pressure was 96 mm Hg in the lisinopril group and 98 mm Hg in
both the NDCCB and atenolol groups. During the study, median
systolic pressure ranged from 132 to 138 mm Hg. The median
diastolic pressure varied from 82 to 86 mm Hg. The mean arterial
pressure ( SD), averaged over all follow-up visits, was 99 4 mm
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Table 3. Number of patients who received more than two
antihypertensive medications by the end of the study"
NDCCB
L VerapamilSR Diltiazem SR Atenolol
____________
(N = 18) (N = 8) (N= 10) (N = 16)
Central alpha 2(11) 0 1(10) 0
agonists
Alpha blockers5 9 (50) 3 (38) 5 (50) 0
1-lydralazinc 0 0 0 4 (25)
Minoxidil 0 0 0 1 (6)
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Fig. 4. The annual values of diastolic blood pressure for each patient in the
ACE inhibitor group (A), j3 blocker group (B) and NDCCB groups (C).
Hg in the lisinopril group, 100 4 mm Hg in the NDCCB group
and 99 3 mm Hg in the atenolol group. During the study there
were no significant differences in the slopes of diastolic blood
pressure among the different groups (P = 0.44). Conversely, an
analysis of systolic blood pressure slopes over the six year period
demonstrated a significantly higher mean systolic pressure in the
atenolol group relative to the lisinopril (P = 0.015) and the
1988 1989 1990 1991 1992 1993 1994
The % of patients in that group is in parentheses.
Methyldopa or clonidine
h Prazosin or doxazosin
"All patients were receiving study drug plus a loop diuretic
NDCCBs (P = 0.007) groups. The decrease in baseline mean
arterial pressure in each group averaged 16 6 mm Hg in the
lisinopril group, 18 6 in the NDCCB group and 15 5 mm Hg
in the atenolol group.
Drug administration
The mean dose of lisinopril over the course of the study was
51 9 milligrams per day, for diltiazem SR, 212 19 milligrams
twice daily and 205 16 milligrams twice daily for verapamil SR.
The atenolol group received a mean dose of 86 9 milligrams per
day of atenolol. If additional blood pressure reduction was
required, furosemide was added. If further blood pressure reduc-
tion was needed, other antihypertensive agents were added. By
the end of the second year, 40 of the 52 (77%) patients were
receiving furosemide for either blood pressure control or man-
agement of peripheral edema. By year four, all patients received
furoscmide. Additionally, by the end of the study 25 of 52 (48%)
patients also received additional blood pressure medications other
than those used for initial randomization. These included alpha
blockers and/or vasodilators such as hydralazine (Table 3).
Changes in creatinine clearance slopes
Each of 52 patients had a minimum of four determinations
(maximum 14) of creatinine clearance during the study. The mean
rate of decline in creatinine clearance was —0.98 0.44 mI/mini
year/1.73 m2 in the lisinopril group, —1.44 0.63 ml/min/year/
1.73 m2 in the NDCCBs group, and —3.48 1.1 ml/min/year/1.73
m2 in the atenolol group. The slope of creatinine clearance
decline for each group is shown in Figure 5. The rate of decline in
creatininc clearance was most pronounced in the group of 41
patients with a baseline serum creatiriine of> 133 mmol per liter.
Among this group the decline in creatinine clearance was —1.06
0.51 ml/niin/ycar/i.73 m2 for the lisinopril group; —1.56 0.84
ml/min/year/1.73 m2 for the NDCCBs group and —3.54 1.39
ml/min/ycar/1.73 m2 for the atenolol group. A comparison of the
atenolol group with either the lisiriopril (P = 0.0001) or NDCCBs
groups (P = 0.004) demonstrated a significant difference in the
renal function decline rates. No significant difference, however,
was noted between the lisinopril and NDCCB groups (P 0.11).
changes in serum creatinine
Among the 52 patients who had four or more determinations of
serum creatinine (median 16 determinations, maximum 33) dur-
ing an average follow-up of 63 months per patient (maximum 73
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months), the mean annual rate of increase in serum ereatinine was
85.7 20.3 micronioles per liter.
Eight of the 52 patients (15.4%) who completed the study
doubled their serum creatinine by study end (P = 0.09). Five of
these eight (63%) were in the atenolol group; four of these five
had to start dialysis by study end. Of the three remaining patients
one was in the lisinopril group and two were in the NDCCB
group. The mean (± sD) baseline serum ereatinine among this
group of eight patients was 194.5 9.7 mmol/liter; the value in the
five patients who received atenolol was 186.1 7.1 mmol/liter.
While an insignificant number of patients doubled their serum
ereatinine from baseline, a significant number increased it by
more than 50% in the atenolol group compared to the other
groups (69% atenolol vs. 17% lisinopril, 22% NDCCBs; P C
0.001).
Changes in urinary protein excretion rate
The mean change from baseline in urinary albumin excretion at
the first three month visit was —0.713 0.628 grams per day in the
lisinopril group, —0.818 0.663 grams per day in the NDCCB
group and 0.168 0.291 grams per day in the atenolol group. The
mean change from baseline proteinuria in each group at 63
Lisinopril NDCCBs Atenolol
(N=18) (W=18) (P16)
E
S
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Baleris et at: Diabetic oephroputhy and hypertension
N 4
—
\\
-0--
—
—
N N
N
Fig. 5. The annual rate of decline in creatinine clearance in 52 patients with NJDDM associated nephropathy. tp < 0.Ot compared to other twu slopes.
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Fig. 6. The mean reduction in athuminuria at 63 months in each of three
groups of participants receiving different antihypertensive medications. ACE1-
angiotensin convcrting enzyme inhibitor, lisinopril; NDCCBs nondihydro-
pyridine calcium channel blockers, ate mInI; atenolal. tp < 0.01 eumpared
to other groups.
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Base 1989 1990 1991 1992 1993 1994
months is shown in Figure 6. The changes in proteinuria over the
course of the study for each patient are shown in Figure 7. The
mean reductions in blood pressure during this same three month
period were comparable (—23 + 5 mm Hg lisinopril group; —22
+ 4 mm Hg NDCCB group and —24 + 5 mm Hg, atenolol group).
A statistical analysis of the changes in proteinuria, using a
Bonferroni correction, demonstrated a statistical difference be-
tween the atenolol group and the lisinopril (P 0.016) and
NDCCBs groups (P = 0.012), respectively. Moreover, changes in
proteinuria over the mean follow-up period of 63 months were
independent of systolic (P = 0.29) or diastolic (I' = 0.79) blood
Adverse event
Cough 4 (22) 0 0 0
Dizziness 4(22) 2(25) 0 3(19)
Constipation 2 (11) 6 (75) 4 (40) 7 (44)
Headache 2(11) 0 2(11) 1(6)
Impotence 0 1(13) 2(20) 9 (56)
Lethargy/fatigue 0 0 0 13 (81)
Exercise Intolerance 0 0 0 7 (43)
Hyperkalemia' 2 (11) 0 0 1(13)
No return to 1(6) 1(13) 1(10) 3 (19)
F/U visits
Pedal edema 1(6) 1(13) 1(10) 2 (13)
Insomnia 0 1(13) 0 6 (38)
Dry mouth 0 0 1(10) 13 (81)
pressure reduction as well as changes from baseline creatinine
clearance (P = 0.48).
Adverse effects of treatment
All adverse events related to drug therapy are summarized in
Table 4. The most common side effect was cough in the lisinopril
group. However, it was tolerable and no one had to discontinue
treatment. During the study there were six deaths and five patients
that needed to start dialysis. Five of the six deaths were due to
cardiovascular causes (1 stroke and 4 myocardial infarctions) and
one from sepsis. Four of the six deaths were in the atenolol group
one in the NDCCB group, diltiazem, and one in the lisinopril
group. Overall the highest side effect profile was noted in the
atenolol group (Table 4). No medication discontinuance was
required due to side effects.
Discussion
It is well known that reduction of blood pressure with a 13
blocker and/or diuretic will slow progression of diabetic nephrop-
athy and reduce proteinuria to a modest degree in diabetic
patients [2, 9, 23]. This study, however, was originally designed to
test the hypothesis that CCBs that maintain reductions in protein-
uria will slow progression of nephropathy associated with NIDDM
to a degree comparable to ACE inhibitors, given similar levels of
blood pressure control. Our data provide the first long-term
evidence that NDCCBs have similar effects to an ACE inhibitor
on both slowing the progression of nephropathy and maintaining
sustained reductions in proteinuria. In contrast, blood pressure
reduction with atenolol was less effective than either lisinopril or
NDCCBs in slowing nephropathy progression. Lastly, this study
demonstrates a strong correlation between proteinuria reduction
and better renal outcomes among patients with NIDDM associ-
ated nephropathy, a finding already appreciated in patients with
IDDM [6, 15, 16].
While the data from this study are compelling for a renopro-
tective effect of long acting verapamil or diltiazem, a number of
A Table 4. Adverse events in patients with NIDDM associated
nephropathy in one of three treatment groups
NDCCBs
Verapamil Diltiazem
SR SR Atendolol
Lisinopril (N 8) (N = 10) (N = 16)
Base 1989 1990 1991
B
1992 1993 1994
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Fig. 7. The annual values of urinary protein excretion for each patient in the
ACE inhibitor group (A), f3 blocker group (B) and NDCCB groups (C).
Treatment withdrawn for one week and each patient given dietary
counseling. Responsible drug reinitiatcd and plasma [Kl remained at
5.5 mmol/liter in each case
Cough was not intractable and did not require change of medication
Defined  6 mEq/liter on any occasion.
C
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factors may account for this observation. These include: differ-
ences between groups in systolic blood pressure control, compli-
ance with antihypertensive medication, number of patients en-
rolled in the study and limitations of creatinine clearance as a
marker of renal function. Lastly, while the statisticians in this
study were blinded to the study groups and all the analyses
predetermined, the study, by virtue of its open label design, has
inherent biases when compared to a double-blind placebo-con-
trolled trial. These and related issues are discussed.
Previous studies in patients with IDDM nephropathy document
that arterial pressure reduction with /3 adrenoreceptor antagonists
reduce the rate of glomerular filtration rate loss when compared
to those whose blood pressure was not controlled [2]. However,
the relative effect of a /3 adrenoreceptor antagonist on slowing
progression of diabetic nephropathy are dwarfed in comparison to
an ACE inhibitor [4, 5, 9, 10, 12, 15, 16, 24]. Moreover, this latter
association has also been described in patients with NIDDM
nephropathy [9, 25]. Our data not only support these observations
with ACE inhibitors, but extend the findings to patients with
marked renal impairment from NIDDM. Moreover, we demon-
strate for the first time that NDCCBs have similar renoprotective
efficacy to the ACE inhibitor, lisinopril, in this group of patients.
The relatively higher level of systolic blood pressure in the
atenolol group, noted at study end, may have contributed to
differences in renal outcome among the groups. Two large scale
clinical studies demonstrate that elevation in systolic pressure
alone is a significant risk factor for progression to end-stage renal
disease [26, 27]. The reasons for the higher level of systolic blood
pressure in the atenolol group are unclear. Two plausible expla-
nations, however, include a potentially greater degree of either
vascular disease or medication non-compliance in this group.
From among the three groups, the atenolol group had the
highest side-effect profile. This may have led to medication
non-compliance in some patients and hence, higher levels of
blood pressure. However, we did not observe similar trends in
diastolic blood pressure. Assuming medication non-compliance
was a factor, one could postulate that this trend in systolic
pressure in the atenolol group might be related to a higher degree
of underlying vascular disease, hence, this group may have poorer
arterial compliance relative to the other groups. Unfortunately,
no formal studies to test this hypothesis were not undertaken. This
combined with the size of the groups precludes any definitive
answer to this query. Moreover, we did not do a formal pill count
to assess medication compliance, other than to monitor time to
medication refill. Therefore, we cannot explain why this group had
high systolic pressures.
A related factor that may explain differences in renal outcome
among the groups is level to which blood pressure was reduced. A
retrospective analysis of the Modification of Dietary Protein in
Renal Disease (MDRD) trial demonstrates that African-Ameri-
cans would not have achieved maximal benefit with regard to
progression of renal disease at the level of blood pressure
reduction set in our study [28]. This trial demonstrated that mean
blood pressure needed to he reduced to less than 92 mm Hg for
progression of renal disease to be slowed to levels comparable
with Caucasians. Whether this was a factor in our study is unclear.
Very few patients actually achieved and maintained blood pres-
sures in this range throughout the study, so we do not have the
statistical power to assess whether this factor contributed to the
differences observed in progression of renal disease.
Reductions in proteinuria are associated with a slowed decline
in renal function in persons with either insulin dependent or
noninsulin dependent diabetes mellitus [2—12, 15, 16, 18]. We
observed similar trends in our NIDDM patients. Furthermore, the
MDRD trial demonstrated that those with higher baseline levels
of proteinuria derived a greater benefit with regard to preserva-
tion of renal function from blood pressure lowering [28]. Our data
support both these observations. Proteinuria reduction was inde-
pendent of both systolic and diastolic pressure reduction as well as
decline in creatinine clearance in our patient groups. Moreover,
we used the most conservative statistical evaluation to assess the
relationship between reductions in arterial pressure and changes
in proteinuria. This suggests that both lisinopril and the NDCCBs
may reduce proteinuria by mechanisms not directly related to
blood pressure lowering. This concept is supported by recent
studies demonstrating direct effects on glomerular membrane
permeability by certain antihypertensive agents [17—18, 29].
Tight glucose control slows progression of early insulin depen-
dent diabetic renal disease, as recently demonstrated by Barbosa
et al [30]. Therefore, good overall glucose control would be
anticipated to slow progression of diabetic nephropathy. In our
study, however, the lowest baseline hemoglobin A1 level was
present in the atenolol group, the group with the fastest decline in
renal function. Moreover, there were no significant differences in
HbA1 levels between the different groups throughout the study.
Therefore, it is unlikely that poor glucose control contributed to
the excessive decline in renal function in the atenolol group.
Another factor that may have contributed to the differences
among the groups is the presence of renal diseases other than
diabetic nephropathy in the patients studied. Some studies report
up tp to 25% of patients with NIDDM have renal diseases other
than diabetic nephropathy to account for their renal mortality [31,
32]. However, a recent analysis of the incidence and prevalence of
noninsulin dependent diabetes, especially among the elderly,
suggests that diabetic nephropathy, as a cause of renal failure is
seriously underestimated [33]. We are aware of this observation
and designed the entry criteria to take this fact into account.
While there is uncertainty about the diagnosis of NIDDM ne-
phropathy without a renal biospy, we feel our entry criteria have
eliminated most patients with other diagnoses that lead to renal
failure. Moreover, five of the 52 patients studied had renal
biopsies performed prior to entry into the study for other reasons,
and all were consistent with a diagnosis of NIDDM associated
nephropathy.
The contribution to differences in progressive renal disease
among the groups may also be related to the use of a less than
ideal marker of renal function, that is, creatinine clearance. While
not an optimal marker of precise renal function, if used consis-
tently to record trends in renal function, it is reproducible and
accurate when compared to itself [34, 35]. Moreover, if adequate
collection is ensured and correction for body mass index applied,
as was done in our study, its reliability is enhanced [34, 35].
Another related factor that must also be taken into account
when reviewing these data are the recent observation that secre-
tion of ereatinine is reduced by CCBs, specifically, diltiazem [36].
While this fact would lead to consistent changes in our NDCCB
group, it may have affected differences between this and the other
groups. However, given that CCBs reduce creatinine secretion,
differences between this and the ACE inhibitor group would be
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lessened not increased. Hence, we do not believe that use of this
marker significantly contributed to the trends seen in our data.
A higher incidence of adverse effects is reported with the use of
atenolol or diuretics compared to ACE inhibitors and CCBs [37,
38]. Our data confirm this observation. Moreover, since all
patients received loop diuretics for most of the follow-up period,
it is clear that the excess in adverse events was related to atenolol.
This increased incidence of adverse effects may have affected
medication compliance, however, as mentioned earlier we did not
collect data on this variable.
Lastly, this study was designed to examine the change in
creatinine clearance slopes and their relationship to changes in
blood pressure and proteinuria. While there were no differences
between the lisinopril and NDCCB creatinine clearance slopes,
this may be the result of an underpowered study. In spite of this,
the mean duration of follow-up, 5.3 years, was adequate to detect
differences. Moreover, slopes were compared using a Bonferroni
correction, which would partially compensate for any sample size
insufficiency. Given this information clinicians should strongly
consider addition of either long acting verapamil or diltiazem to
either an ACE inhibitor or diuretic to achieve sufficient blood
pressure control. Moreover, if patients with renal insufficiency
cannot tolerate an ACE inhibitor secondary to either hyperkale-
mia or cough, long acting NDCCBs should be considered as
alternatives for blood pressure reduction. Please note, however,
that further large scale clinical trials are required to confirm these
findings.
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